Bernstein Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $110
Astra, Merck Drugs Set to Shake Up Liver Cancer Treatment
Bernstein Sticks to Their Hold Rating for Merck & Company (MRK)
S&P 500 Positive for 'First Five Days,' Huang Sees Decades till Quantum | Wall Street Today
Wednesday Market Falls, Quantum Computing Pulls Back Hard on Treasury Yield Crunch | Live Stock
Merck Rival Summit Draws New Buy From Truist on Deal Prospects
Merck, Johnson & Johnson Share Losses Lead Dow's 180-Point Fall
Global Equities Roundup: Market Talk
Merck's Near-Term Growth Path Uncertain -- Market Talk
Merck Gets Expanded Approval From China for Its HPV Vaccine in Males
Salesforce To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday
Truist Financial Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $110
UBS Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $120
Express News | Merck & Co Inc : Truist Securities Cuts Target Price to $110 From $130
This Adobe Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet
Merck Cut to Hold From Buy by Truist Securities
U.S. Stock Outlook | All three Equity Index futures are down, new news on Trump's tariffs, the U.S. stock market will be closed on Thursday.
On January 8th (Wednesday) during Pre-Market Trading, the three major Equity Index futures in the U.S. all fell.
Merck & Co Analyst Ratings
Merck's male HPV vaccine has been approved domestically for the first time. Industry insiders believe this will promote the future approval of domestic products under development.
① Gardasil has become the first and currently the only approved HPV vaccine for men in China. ② Industry experts believe that the approval of the new indication is a new exploration in terms of pharmacological principles and other aspects. ③ Currently, companies such as Kang Li Wei Shi and Beijing Wantai Biological Pharmacy Enterprise have made arrangements in this field.